Advanced BioScience Laboratories, Inc. (ABL), a global contract development and manufacturing organization (CDMO) and contract research organization (CRO) for biotherapeutics, oncolytics and vaccines has completed the aseptic fill/finish of a novel COVID-19 vaccine candidate for a confidential customer.
 
ABL said it readied the fill/finish line within a week to vial the vaccine for upcoming clinical trials.
 
In addition to this completed effort, ABL said it is in negotiations with multiple industry and U.S. government clients to apply its capabilities to support COVID-19 vaccine and therapeutic product development. 
 
“We are in active discussions with a number of clients to support the manufacture and testing of COVID-19 vaccine candidates,” said Jarlath Keating, chief executive officer, ABL. “We understand the need to be flexible and responsive in order to best support the rapid development programs our clients have established in the fight against the spread of COVID-19.  ABL’s global GMP operations are in place to meet the increased capacity requirements, while still maintaining strict compliance with regulatory authorities.”